Benzinga · Mar 11, 2026
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $1008 to $40.
NASDAQ · GRI
GRI Bio, Inc.
Healthcare · Biotechnology
$1.81
Down-$0.01 (-0.55%)
Updated Sep 17, 2026, 5:16 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.27M
- P/E ratio
- -0.11
- Dividend yield
- 0.00%
- 52-week range
- $1.36 – $3.36
- Volume
- 48.01K
- Avg. volume
- 1.26M
Price performance
GRI price history
1M range · 20 trading sessions · Daily adjusted prices
GRI closed at $1.81 after 20 trading sessions, up 4.62% for the selected period.
- Last close
- $1.81
- Period change
- +4.62%
- Period low
- $1.65
- Period high
- $2.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.81 | $1.85 | $1.75 | $1.81 | 48.01K |
| Sep 15, 2026 | $1.89 | $1.89 | $1.80 | $1.82 | 69.48K |
| Sep 14, 2026 | $1.86 | $1.97 | $1.86 | $1.89 | 105.31K |
| Sep 11, 2026 | $1.99 | $2.05 | $1.85 | $1.90 | 131.91K |
| Sep 10, 2026 | $1.79 | $2.00 | $1.78 | $1.94 | 214.31K |
| Sep 9, 2026 | $1.97 | $1.97 | $1.76 | $1.80 | 201.65K |
| Sep 8, 2026 | $2.61 | $2.67 | $1.90 | $2.00 | 733.75K |
| Sep 4, 2026 | $2.34 | $3.36 | $2.33 | $2.88 | 7.46M |
| Sep 3, 2026 | $2.08 | $2.50 | $2.01 | $2.29 | 1.61M |
| Sep 2, 2026 | $1.92 | $2.02 | $1.87 | $2.00 | 85.83K |
| Sep 1, 2026 | $1.90 | $1.98 | $1.84 | $1.91 | 42.45K |
| Aug 31, 2026 | $1.93 | $1.97 | $1.86 | $1.92 | 51.89K |
| Aug 28, 2026 | $2.05 | $2.07 | $1.91 | $1.92 | 34.87K |
| Aug 27, 2026 | $1.8208 | $2.10 | $1.8208 | $2.07 | 78.64K |
| Aug 26, 2026 | $1.96 | $1.96 | $1.8302 | $1.91 | 44.26K |
| Aug 25, 2026 | $1.80 | $1.98 | $1.785 | $1.96 | 127.51K |
| Aug 24, 2026 | $1.80 | $1.94 | $1.759 | $1.79 | 267.4K |
| Aug 21, 2026 | $1.71 | $1.73 | $1.65 | $1.65 | 83.15K |
| Aug 20, 2026 | $1.73 | $1.77 | $1.6644 | $1.67 | 27.59K |
| Aug 19, 2026 | $1.75 | $1.7925 | $1.69 | $1.73 | 61.64K |
Latest GRI news
The latest Smart Investors Daily articles mentioning GRI.
Stock researchCompany · Overview
GRI research
Overview
Company profile and research snapshot.
Company profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2026 | Ascendiant Capital | Buy | — |
| Mar 11, 2026 | Ascendiant Capital | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
| Sep 22, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
proactiveinvestors.co.uk · Oct 27, 2025
Grainger says UK's Renters' Rights Bill 'provides stability for investors and landlords'
Grainger Plc (LSE:GRI), the UK's largest private rental landlord, has welcomed the government's Renters' Rights Bill, which has been passed by the House of Commons and is expected to be passed into law next year. Key provisions in the Bill, which is due to receive royal assent by the end of 2025, include the abolition of no-fault evictions, the introduction of open market annual rent reviews, and support for pet-friendly policies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
